Renal denervation as a high blood pressure treatment is looking less exciting by the day, with the latest bad news coming from Covidien. The Dublin, Ireland–based medical device giant said Tuesday that it will exit its OneShot renal ...
Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan® Dx Assay. This assay is intended for the postnatal detection of DNA copy ...
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
As co-ordinator of the European project 'ReBioStent', Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the ...
Tags: Construction, Decoration, Ceram-Lead Project
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine. Designed for infants, it targets whooping cough, a common and, ...
Quick treatment with a new "microparticle" therapy might significantly reduce the damage caused by a heart attack, according to a new study conducted in mice. After a heart attack, much of the damage to the heart muscle is caused by ...
Posted in Cardiovascular by Chris Newmarker on January 15, 2014 Boston Scientific CEO Mike Mahoney remains optimistic about renal denervation and the company’s Vessix platform, even though Medtronic’s Symplicity system failed ...
Tags: Boston Scientific, Mike Mahoney, renal denervation, Vessix platform
A new gene therapy that successfully treated a rare eye disease in clinical trials could prove the key to preventing more common inherited causes of blindness, researchers say. In six male patients, doctors used a virus to repair a ...
Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in ...
Most clinical studies of vitamins are "flawed by poor methodology", review finds Most large clinical trials of vitamin supplements, including those that have concluded supplements are of no value or even harmful, have a “flawed ...
Tags: vitamin supplements, flawed methodology, useless, micronutrients
Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients ...
Tags: Altheus Therapeutics, enrollment, ZA201, Zoenasa®Rectal Gel
The drugs Mekinist and Tafinlar were approved for combination treatment of advanced melanoma skin cancer, the U.S. Food and Drug Administration announced Friday. The two medicines "are the first drugs approved for combination treatment of ...
Tags: FDA, 2-Drug Combo Treatment, Combo Treatment for Advanced Melanoma
Farxiga (dapaglifozin) has been approved by the U.S. Food and Drug Administration to treat adults with type 2 diabetes, the agency said Wednesday in a news release. The drug, to be used for blood sugar control along with proper diet and ...
Tags: Farxiga, Type 2 Diabetes, Medicine News
Cardica, a medical device company, has received 510(k) approval from the US Food and Drug Administration (FDA) for its MicroCutter Xchange 30 device and blue staple cartridge for medium thickness tissue. The company has designed the ...
Tags: Cardica, medical device